{"id":463620,"date":"2026-03-10T00:00:00","date_gmt":"2026-03-10T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0008-2025-biopharma-prostate-cancer-landscape-forecast-disease-landscape-forecast-g7\/"},"modified":"2026-03-31T10:23:19","modified_gmt":"2026-03-31T10:23:19","slug":"dlsfon0008-2026-biopharma-prostate-cancer-landscape-forecast-disease-landscape-forecast-g7","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0008-2026-biopharma-prostate-cancer-landscape-forecast-disease-landscape-forecast-g7\/","title":{"rendered":"Prostate Cancer &#8211; Landscape &#038; Forecast &#8211; Disease Landscape &#038; Forecast (G7)"},"content":{"rendered":"<p>Hormonal agents dominate the treatment landscape for prostate cancer and are routinely used in all lines of therapy. Second-generation hormone therapies have expanded beyond metastatic castrate-resistant prostate cancer (<abbr title=\"metastatic castrate-resistant prostate cancer\">mCRPC<\/abbr>), dominating current treatment of nonmetastatic <abbr title=\"castrate-resistant prostate cancer\">CRPC<\/abbr> and hormone-sensitive prostate cancer (<abbr title=\"hormone-sensitive prostate cancer\">HSPC<\/abbr>). The continued uptake of hormonal therapies, plus the expected label expansions of targeted agents (e.g., J&#038;J Innovative Medicine\u2019s Akeega, Pfizer\u2019s talazoparib) and radioligand therapies (Novartis\u2019s Pluvicto), and anticipated approvals of emerging therapies (e.g., AstraZeneca\u2019s saruparib and Merck\u2019s opevesostat), will drive robust market growth over the 2024-2034 forecast period.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What is the estimated size of the clinically and commercially relevant drug-treatable prostate cancer populations, and how will drug-treatment rates vary by geography, setting, and over time?<\/li>\n<li>How will the prostate cancer market evolve over the 10-year forecast period? What are their drivers and constraints?<\/li>\n<li>What are interviewed experts\u2019 insights on the current treatment options for prostate cancer?\u00b7 How will the adoption and anticipated label expansions of biomarker-driven therapies, such as <abbr title=\"poly ADP (adenosine diphosphate)-ribose polymerase\">PARP<\/abbr> inhibitors and <abbr title=\"prostate-specific membrane antigen\">PSMA<\/abbr>-targeted radionuclide therapies, reshape the prostate cancer treatment landscape?<\/li>\n<li>What is the clinical and commercial potential of emerging regimens, like opevesostat and saruparib? How are they likely to be positioned in the market?<\/li>\n<\/ul>\n<p><strong>Geography: <\/strong>United States, <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr>, Japan<\/p>\n<p><strong>Primary research:<\/strong> 18 country-specific interviews with thought-leading medical oncologists and urologists; supported by survey data collected for this and other Clarivate research<\/p>\n<p><strong>Epidemiology:<\/strong> Incidence of prostate cancer by country, segmented by risk of biochemical recurrence and <abbr title=\"primary tumor, regional lymph node, and distant metastasis\">TNM<\/abbr> staging; market-relevant drug-treatable and drug-treated populations<\/p>\n<p><strong>Forecast:<\/strong> 10-year, annualized, drug-level sales and patient share of key prostate cancer therapies through 2034, segmented by brands \/ generics and epidemiological subpopulations<\/p>\n<p><strong>Drug treatments: <\/strong>Coverage of key current and emerging therapies<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n<ul>\n<li>Optimize your long-term disease and development strategy.<\/li>\n<li>Quantify market potential for your pipeline assets and those of your competitors.<\/li>\n<li>Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.<\/li>\n<li>Gauge the commercial outlook and impact of key market events.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-463620","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-prostate-cancer","biopharma-therapy-areas-solid-tumors","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/463620","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":3,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/463620\/revisions"}],"predecessor-version":[{"id":575183,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/463620\/revisions\/575183"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=463620"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}